2016 Industry Pressures Drive Mixed Healthcare Investor Sentiment in 4th Quarter

NEW YORK–(BUSINESS WIRE)– Although 2016 overall turned out to be a mixed year for healthcare,
heightened investor activity in the fourth quarter points to a case for
guarded optimism heading into 2017, according to the latest Financing,
Licensing and M&A Quarterly Report from BioPharm
Insight (BPI).

Get the Report: http://www.biopharminsight.com/financing-licensing-ma-4q16

BPI, the most comprehensive life science market intelligence and
analytics solution, reports that initial public offerings (IPOs) saw the
most dramatic increase late in the year, going from 21 in the third
quarter to 35 in the fourth quarter. The value of IPO deals in the
fourth quarter jumped dramatically, going from $1.75 billion in the
third quarter to $8.15 billion. The largest healthcare IPO in the
quarter was South Korea’s Samsung BioLogics (KRX:20794), which raised
$1.9 million and was listed on the Korean Exchange.

“The big question is whether the IPO window in 2017 will remain open or
if the unfavorable market sentiment that dominated the first three
quarters of 2016 will return,” said Querida Anderson, editor in chief at BioPharm
Insight.

Healthcare mergers and acquisitions (M&As), venture financing rounds and
licensing deals were a mixed bag in the fourth quarter, according to
BPI, with global numbers for each category being up, but the value of
the deals showing declines of 5 percent, 13 percent and 17 percent,
respectively.

“Even though Donald Trump’s stance on drug pricing was largely unknown,
his surprising victory in the U.S. presidential election created
momentum for a healthcare market rally in November,” said Peter Murphy,
senior editorial analyst at BioPharm Insight. “The prevailing
wisdom is that there will be no major pricing reform under a new
administration and Congress, with overall signs for M&A activity
pointing up in large part due to the Republican Party’s stances on tax
reform and cash repatriation.”

The report provides snapshots of the 10 largest healthcare IPOs, M&A
deals, drug licensing deals and venture financing rounds in the fourth
quarter, as well as five-year regional trends around the globe. It also
highlights a selection of BPI’s editorial coverage based on interviews
with C-level executives about their 2017 financing requirements and
licensing plans.

In M&A activity, the report discusses the pipeline challenges Actelion
(VTX:ATLN) continues to experience and Johnson & Johnson’s (NYSE:JNJ)
bid to acquire the company. BPI also examines the specialty pharmacy
acquisition strategy of PDL BioPharma (NASDAQ:PDLI); the interest of
some Big Pharma companies in acquiring female health drugmaker Palatin
Technologies (NYSEMKT:PTN); Ipsen’s (EPA:IPN) oncology and neuroscience
acquisition strategy; and Galapagos’ (AMS:GLPG) recent cash infusions
that is allowing the company to develop more drugs on its own.

Learn more about Financing, Licensing and M&A Activity in the 4^th
Quarter with BioPharm Insight’s full report:

http://www.biopharminsight.com/financing-licensing-ma-4q16

Tweet:
#Healthcare #IPOs leap past $8B in 4Q 2016 – @BioPharmInsight
Financing, Licensing and M&A Report: http://bit.ly/bpi4q16

About BioPharm Insight

BioPharm Insight is the most comprehensive life science market
intelligence and analytics solution, featuring a team of investigative
journalists writing exclusive news and thousands of healthcare data
points, aggregated into one centralized source. In addition to the
proprietary articles, BioPharm Insight is currently tracking
250,000 management and R&D contacts, 7,500 biopharma companies with full
pipeline data, 120,000 investigational and approved drug profiles,
28,000 M&A and licensing deals, 10,000 extended sales forecasts and
epidemiology profiles for hundreds of indications.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170124005454/en/